Supported Projects

Immune Development in Early Life (IDEAL)

IDEAL aims to characterize molecular and cellular signatures in plasma and nasal secretions over time, in children from 8 weeks to 5 years of age, to assess their correlation with key clinical outcomes including health as well as poor vaccine responsiveness, frequent respiratory infections and/or asthma. 

IMmunoPhenotyping Assessments in a COVID19 Cohort (IMPACC)

The IMMuno Phenotyping Assessment in a COVID-19 Cohort (IMPACC) is a NIAID-supported study that aims to track the immune responses of people hospitalized with COVID-19 in 15 research sites across the United States. 

Precision Vaccines Program -Internal Projects

Multi-omic projects being conducted with the Precision Vaccines Program (PVP).

International Network of Special Immunization Services (INSIS)

The purpose of INSIS is to address knowledge gaps in our understanding of the causes of adverse events of special interest following vaccination, risk factors for developing AEFIs, and determine the best way to immunize individuals with prior AEFIs or risk factors for developing AEFIs. While the initial focus will be on AEFIs following COVID-19 vaccination, INSIS’s mandate can be broadened to other vaccines in the future.

Expanded Program on Immunization Consortium- Human Immunology Project Consortium (EPIC-HIPC)

The central theme in this Human Immunology Project Consortium (HIPC) proposal is the use of transcriptomics,proteomics, as well as immune-phenotyping of the cellular and soluble blood compartment collectively referred toas “OMIC” technologies, to characterize neonatal vaccine responses in relation to established immune correlatesof protection (CoP).